Corcept financial update, share buyback

 

• Fourth quarter revenue of $135.4 million, a 31 percent increase
  over the same period in 2022
• Full year 2023 revenue of $482.4 million, a 20 percent increase over 2022
• 2024 revenue guidance of $600 – $630 million
• Cash and investments of $425.4 million as of December 31, 2023
• Announcement of $200 million stock repurchase program

https://www.globenewswire.com/news-release/2024/01/08/2805399/0/en/Corcept-Therapeutics-Provides-Financial-Update-and-Announces-Stock-Repurchase-Program.html